Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Amundi in connection with the acquisition of Lyxor Asset Management from Société Générale for EUR 825 million
Mandate

Vinge advises Amundi in connection with the acquisition of Lyxor Asset Management from Société Générale for EUR 825 million

September 08, 2021 Employment and Benefits Banking and Finance Corporate Tax

Vinge has advised Amundi, a division of the Crédit Agricole group, in connection with its acquisition of Lyxor from Société Générale.

Lyxor is a pioneer within, and the third largest actor in Europe with regard to exchange‑traded funds (ETFs), and via this acquisition Amundi will thereby strengthen its position as the European lead actor in the fast‑growing market for ETFs. The transaction is subject to customary approvals by public authorities and is expected to be completed not later than February 2022.

Vinge’s team consisted of responsible partner Fredrik Wilkens (Project Manager), Henrik Schön, Anton Sjökvist (Fund Issues), Åsa Gotthardson, Sara Strandberg and Ebba Svenburg (Employment Law), Maria Schultzberg, Henrik Wastenson and Karolin Ekström (Tax) as well as Ulf Nilsson (VAT).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025